Moving the Needle

Moving the Needle provides updates from PATH’s Center for Vaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing-country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technologies. It includes updates on our progress, partnerships, and specific activities.

This is one of two newsletters published by CVIA. To learn more about CVIA’s vaccine uptake and access work, see Immunization Matters.

September 2022

• Farewell and thank you to the Global Head of CVIA
• Monoclonal antibody shows promise in preventing malaria
• Universal reagent development for sIPV D antigen
• Early closure of pivotal Phase 3 study of injectable rotavirus vaccine candidate
• Q & A with John Tanko Bawa
• Clinical updates
• Resources and opportunities

June 2022

• Typhoid conjugate vaccine candidate aims to increase global supply
• Register and submit an abstract for VASE 2022!
• New online library supports maternal immunization for COVID-19 and beyond
• Q & A with John Konz
• Clinical updates
• Resources and opportunities

January 2022

• PATH assists Chinese COVID-19 vaccine suppliers to address pandemic needs
• Developing the next generation of malaria vaccines
• Q & A with Mark Alderson
• Resources and opportunities

September 2021

• Clinical data shows potential new use for RTS,S/AS01E malaria vaccine
• Manufacturers advance egg-based COVID-19 vaccine in clinical development
• Global roadmap to defeat meningitis formally launches
• Q & A with Kutub Mahmood
• Clinical updates
• Resources and opportunities

May 2021

• New egg-based COVID-19 vaccine candidate enters clinical studies
• PATH evaluates new rotavirus vaccine candidates and regimens
• VASE Conference postponed to 2022; new virtual symposium in September
• Q & A with Jorge Flores
• Clinical updates
• Resources and opportunities

January 2021

• Evidence base grows for novel oral polio vaccine against poliovirus type 2
• PATH and partners advance yellow fever vaccine for global use
• World Health Assembly approves global strategy to defeat meningitis
• Q & A with Kristen Lewis
• Clinical updates
• Resources and opportunities

September 2020

• Advancing malaria vaccine development at all stages of the parasite’s lifecycle
• New PCV advancements aim to increase pneumonia prevention efforts
• Expanding access to HPV vaccines
• Q & A with Simone Blayer
• Clinical updates
• Resources and opportunities

May 2020

• Baylor College of Medicine and PATH partner to advance COVID-19 vaccine
• Pandemic prevention through vaccine development
• VASE Conference postponed to August 2021
• Q & A with Deborah Atherly
• Clinical updates
• Resources and opportunities

January 2020

• Newly WHO-prequalified vaccine to advance pneumococcal disease prevention
• ETEC vaccine candidate demonstrates an immune response in infants
• Join PATH for the 2020 VASE Conference in Washington, DC
• A successful partnership to develop a next-generation malaria vaccine
• Q & A with Niranjan Bhat
• Clinical updates
• Resources and opportunities

September 2019

• Unique study design advances novel oral polio vaccine development
• Polyvalent meningococcal conjugate vaccine enters late-stage clinical study
• Q & A with Hope Randall
• Clinical updates
• Resources and opportunities

May 2019

• World's first malaria vaccine introduced in sub-Saharan Africa
• CVIA expands vaccine manufacturing support
• PATH and partners to develop vaccine against Nipah virus
• New assay to expedite the development of vaccines against bacterial pathogens
• Q & A with Stan Cryz
• Clinical updates
• Resources and opportunities

January 2019

• Paving the way for a groundbreaking vaccine
• WHO endorses first International Standard for assessment of sIPV
• Defending the world from influenza
• Q & A with Cynthia Lee
• Clinical updates
• Resources and opportunities

September 2018

• A new look for our newsletter
• Combining different types of malaria vaccines may improve efficacy
• Strong CVIA presence at International Rotavirus Symposium
• Q & A with Bruce Innis
• Clinical updates
• Resources and opportunities

May 2018

• PATH co-sponsors premier international pneumococcal conference
• Expert insights shared at the 7th MIM Pan African Conference
• Workshop co-hosted by PATH reviews ETEC assays and reagents
• Addressing vaccine development challenges and opportunities
• Q & A with Francesco Berlanda Scorza
• Resources and opportunities

January 2018

• New vaccine products achieve World Health Organization prequalification
• Strengthening vaccines for the polio endgame era
• Collaboration reveals a structural clue to attacking malaria’s “Achilles heel”
• Register for the 2018 VASE Conference!
• Q & A with Nancy Hosken
• Clinical updates
• Resources and opportunities

October 2017

• CVIA strengthens maternal immunization work
• New rotavirus vaccine demonstrates significant efficacy
• Strong CVIA presence at global enteric vaccines meetings
• Q & A with Rahnuma Wahid
• Clinical updates
• Resources and opportunities

July 2017

• Affordable pneumococcal vaccine candidate enters late-stage development
• New partnership conducts first-in-human test of novel malaria vaccine approach
• 2018 VASE Conference welcomes workshop ideas
• PATH receives 2017 Upshot Award in Global Prevention
• Q & A with Alan Fix
• Clinical updates
• Resources and opportunities

April 2017

• New partnership to advance non-replicating rotavirus vaccine development
• Promising new study results for rotavirus vaccine candidate
• Spotlight: CVIA’s regulatory team
• Q & A with Ulrike Wille-Reece
• Clinical updates
• Resources and opportunities

January 2017

• PATH begins work on Group B Streptococcus vaccine
• New study will test alternate regimen of malaria vaccine
• Data visualization tool reveals burden of ETEC and Shigella
• Q & A with Francine McCutchan
• Clinical updates
• Resources and opportunities

October 2016

• Welcome to our new e-newsletter!
• New funding to develop a novel monovalent oral polio vaccine
• Positive Phase 1 results for Vietnam-made seasonal influenza vaccine
• Alternate dosing regimen of RTS,S/AS01 shows increased efficacy
• Q & A with Dr. David C. Kaslow
• Clinical updates
• Resources and opportunities